Trial intelligence / Profile preview

ARNICA: Antiviral treatment for chronic hepatitis C in illicit drug users

2008-001283-37Phase 4Active

Sponsor: ASST Spedali Civili di Brescia
Start: Apr 2008
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, single-arm trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection, sponsored by ASST Spedali Civili di Brescia. Primary endpoints: Sustained virologic response (SVR) and Tolerability and safety of antiviral therapy. Started Apr 2008; status: active.

Drugs

peginterferon alfa-2bribavirin

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2008-001283-37.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-001283-37.